Download PDF
Psychother Psychosom Med Psychol 2005; 55(1): 36-48
DOI: 10.1055/s-2004-834580
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Psychische Erkrankungen und Immunsystem

The Immunology of Psychiatric DisordersVolker  Arolt1 , Matthias  Rothermundt1
  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Münster
Further Information

Publication History

Eingegangen: 28. Oktober 2003

Angenommen: 30. November 2004

Publication Date:
13 January 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Veränderungen von Immunfunktionen im Zusammenhang mit psychischen Erkrankungen haben im vergangenen Jahrzehnt zunehmende wissenschaftliche Aufmerksamkeit erregt. Inzwischen konnten für die weitere Forschung wegweisende, wenn auch nicht unumstrittene Befunde insbesondere zu Depressionserkrankungen und Schizophrenien erhoben werden. In der vorliegenden Arbeit wird auf diese Befunde im Detail Bezug genommen; zusätzlich werden Beobachtungen bei postraumatischen Belastungsstörungen sowie Panik- und Zwangsstörungen referiert. Auf dieser Grundlage werden Überlegungen zu weiterführenden Forschungsperspektiven angestellt.

Abstract

Immunological alterations in psychiatric disorders have gained increasing scientific attention throughout the last decade. Particularly in two disorders, major depression and schizophrenia, some substantial findings have been reported. Although such results stand not uncontradicted, they nevertheless stimulate current research into the neurobiological underpinnings of these diseases. In this review, immunological dysfunctions in major depression and schizophrenia are described in detail, together with studies on posttraumatic stress disorders, panic- and obsessive-compulsive disorders. Possible future research directions are delineated.

Key words

Immunology - cytokine - depression - posttraumatic stress disorder - anxiety - schizophrenia

Literatur

  • 1 Arolt V, Rothermundt M, Peters M, Leonard B. Immunological research in clinical psychiatry: report on the consensus debate during the 7th Expert Meeting on Psychiatry and Immunology.  Mol Psychiatry. 2002;  7 822-826
    CrossrefPubMedGoogle Scholar
  • 2 Bartrop R W, Lazarus L, Luckhurst E, Kiloh L G. Depressed lymphocyte function after bereavement.  Lancet. 1977;  83 834-836
    PubMedGoogle Scholar
  • 3 Marazitti D, Ambrogi F, Vanacore R. et al . Immune cell imbalance in major depressive and panic disorders.  Neuropsychobiol. 1992;  26 23-26
    PubMedGoogle Scholar
  • 4 Müller N, Hofschuster E, Ackenheil M. et al . Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis.  Progr Neuropsychopharmacol Biol Psychiatry. 1993;  17 713-730
    PubMedGoogle Scholar
  • 5 Legros S, Mendlewicz J, Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders.  Eur Arch Psychiatry Clin Neurosci. 1985;  235 9-11
    PubMedGoogle Scholar
  • 6 Seidel A, Arolt V, Hunstiger M. et al . Cytokine production and serum proteins in depression.  Scand J Immunol. 1995;  41 534-538
    CrossrefPubMedGoogle Scholar
  • 7 Berk M, Wadee A A, Kuschke R H, O'Neill-Kerr A. Acute phase proteins in major depression.  J Psychosom Res. 1997;  43 529-534
    CrossrefPubMedGoogle Scholar
  • 8 Joyce P R, Hawes C R, Mulder R T. et al . Elevated levels of acute phase proteins in major depression.  Biol Psychiatry. 1992;  32 1035-1041
    CrossrefPubMedGoogle Scholar
  • 9 Maes M, Scharpe S, Bosmans E. et al . Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness.  Progr Neuropsychopharmacol Biol Psychiatry. 1992 a;  16 501-515
    PubMedGoogle Scholar
  • 10 Maes M, Delanghe J, Ranjan R. et al . Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs.  Psychiatry Res. 1997 c;  66 1-11
    CrossrefPubMedGoogle Scholar
  • 11 Song C, Dinan T, Leonard B E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls.  J Affect Disord. 1994;  30 283-288
    CrossrefPubMedGoogle Scholar
  • 12 Maes M, Planken M Van der, Stevens W J. et al . Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression.  J Psychiatr Res. 1992 c;  26 125-134
    CrossrefPubMedGoogle Scholar
  • 13 Seidel A, Arolt V, Hunstiger M. et al . Major depressive disorder is associated with elevated monocyte counts.  Acta Psychiatr Scand. 1996 a;  94 198-204
    CrossrefPubMedGoogle Scholar
  • 14 Castilla-Cortazar I, Castilla A, Gurpegi M. Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders.  J Physiol Biochem. 1998;  54 203-215
    PubMedGoogle Scholar
  • 15 Irwin M, Smith T L, Gillin J C. Low natural killer cytotoxicity in major depression.  Life Sci. 1987;  41 2127-2133
    CrossrefPubMedGoogle Scholar
  • 16 Darko D F, Gillin J C, Risch S C. et al . Immune Cells and the Hypothalamic-Pituitary Axis in Major Depression.  Psychiatry Res. 1988;  25 173-179
    CrossrefPubMedGoogle Scholar
  • 17 Maes M, Meltzer H Y, Stevens W. et al . Natural Killer Cell Activity In Major Depression: Relation To Circulating Natural Killer Cells, Cellular Indices Of The Immune Response, And Depressive Phenomenology.  Progr Neuropsychopharmacol Biol Psychiatry. 1994 c;  18 717-730
    PubMedGoogle Scholar
  • 18 Anesi A, Franciotta D, Paolo E Di. et al . PHA-Stimulated Cellular Immune Function And T-Lymphocyte Subsets In Major Depressive Disorders.  Funct Neurol. 1994;  9 17-22
    PubMedGoogle Scholar
  • 19 McAdams C, Leonard B E. Neutrophil and monocyte phagocytosis in depressed patients.  Progr Neuropsychopharmacol Biol Psychiatry. 1993;  17 971-984
    PubMedGoogle Scholar
  • 20 Maes M, Bosmans E, Suy E. et al . Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1beta and soluble interleukin-2 receptor production.  Acta Psychiatr Scand. 1991 a;  84 379-386
    CrossrefPubMedGoogle Scholar
  • 21 Maes M, Bosmans E, Meltzer H Y. et al . Interleukin-1beta: A putative mediator of HPA axis hyperactivity in major depression?.  Am J Psychiatry. 1993 a;  150 1189-1193
    PubMedGoogle Scholar
  • 22 Weizman R, Laor N, Podliszewski E. et al . Cytokine production in major depressed patients before and after clomipramine treatment.  Biol Psychiatry. 1994;  35 42-47
    CrossrefPubMedGoogle Scholar
  • 23 Maes M, Meltzer H Y, Bosmans E. et al . Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.  J Affect Dis. 1995 b;  34 301-309
    PubMedGoogle Scholar
  • 24 Maes M, Bosmans E, Jongh R de . et al . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.  Cytokine. 1997 a;  9 853-858
    CrossrefPubMedGoogle Scholar
  • 25 Haack M, Hinze-Selch D, Fenzel T. et al . Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.  J Psychiatr Res. 1999;  33 407-418
    CrossrefPubMedGoogle Scholar
  • 26 Maes M, Meltzer H Y, Buckley P, Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.  Eur Arch Psychiatry Clin Neurosci. 1995c;  244 325-329
    PubMedGoogle Scholar
  • 27 Maes M. Evidence for an immune response in major depression: a review and hypothesis.  Progr Neuropsychopharmacol Biol Psychiatry. 1995 d;  19 11-38
    CrossrefPubMedGoogle Scholar
  • 28 Anisman H, Ravindran A V, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features.  Mol Psychiatry. 1999;  4 182-188
    CrossrefPubMedGoogle Scholar
  • 29 Darko D F, Gillin J C, Risch S C. et al . Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression.  Biol Psychiatry. 1989;  26 145-155
    CrossrefPubMedGoogle Scholar
  • 30 Natelson B H, Denny T, Zhou X D. et al . Is depression associated with immune activation?.  J Affect Disord. 1999;  53 179-184
    CrossrefPubMedGoogle Scholar
  • 31 Inglot A D, Leszek J, Piasecki E, Sypula A. Interferon responses in schizophrenia and major depressive disorders.  Biol Psychiatry. 1994;  35 464-473
    CrossrefPubMedGoogle Scholar
  • 32 Maes M, Scharpe S, Meltzer H Y. et al . Increased neopterin and interferon-gamma secretion and lower avaibility of l-tryptophan in major depression: further evidence for an immune response.  Psychiatry Res. 1994 d;  54 143-160
    CrossrefPubMedGoogle Scholar
  • 33 Seidel A, Arolt V, Hunstiger M. et al . Increased CD56+Natural Killer Cells and Related Cytokines in Major Depression.  Clin Immunol Immunopathol. 1996 b;  78 83-85
    CrossrefPubMedGoogle Scholar
  • 34 Rothermundt M, Arolt V, Fenker J. et al . Different immune patterns in melancholic and non-melancholic major depression.  Eur Arch Psychiatry Clin Neurosci. 2001 b;  251 90-97
    CrossrefPubMedGoogle Scholar
  • 35 Rothermundt M, Arolt V, Peters M. et al . Inflammatory markers in major depression and melancholia.  J Affect Disord. 2001 c;  63 93-102
    CrossrefPubMedGoogle Scholar
  • 36 Konsman J P, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications.  Trends Neurosci. 2002;  25 154-159
    CrossrefPubMedGoogle Scholar
  • 37 Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.  Gen Hosp Psychiatry. 2003;  25 34-38
    PubMedGoogle Scholar
  • 38 Capuron L, Ravaud A, Neveu P J. et al . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.  Mol Psychiatry. 2002 b;  7 468-473
    CrossrefPubMedGoogle Scholar
  • 39 Widner B, Laich A, Sperner-Unterweger B. et al . Neopterin production, tryptophan degradation, and mental depression - what is the link?.  Brain Behav Immun. 2002;  16 590-595
    CrossrefPubMedGoogle Scholar
  • 40 Reichenberg A, Yirmiya R, Schuld A. et al . Cytokine-associated emotional and cognitive disturbances in humans.  Arch Gen Psychiatry. 2001;  58 445-452
    CrossrefPubMedGoogle Scholar
  • 41 Pollmächer T, Haack M, Schuld A. et al . Low levels of circulating inflammatory cytokines - Do they affect human brain functions?.  Brain Behav Immun. 2002;  16 525-532
    CrossrefPubMedGoogle Scholar
  • 42 Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for „free chow” and „earned” sucrose intake.  Psychopharmacol. 2003;  165 413-418
    PubMedGoogle Scholar
  • 43 Capuron L, Gumnick J F, Musselman D L. et al . Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.  Neuropsychopharmacol. 2002 a;  26 643-652
    CrossrefPubMedGoogle Scholar
  • 44 Wong C M. Post-traumatic stress disorder: advances in psychoneuroimmunology.  Psychiatr Clin North Am. 2002;  25 369-383
    CrossrefPubMedGoogle Scholar
  • 45 Boscarino J A, Chang J. Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications.  Psychosom Med. 1999;  61 378-386
    PubMedGoogle Scholar
  • 46 Weiss D W, Hirt R, Tarcic N. et al . Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks.  Behavioral Med. 1996;  22 5-14
    PubMedGoogle Scholar
  • 47 Wilson S N, Kolk B van der, Burbridge J. et al . Phenotype of blood lymphocytes in PTSD suggests chronic immune activation.  Psychosomatics. 1999;  40 222-225
    PubMedGoogle Scholar
  • 48 Laudenslager M L, Aasal R, Adler L. et al . Elevated cytotoxicity in combat veterans with long-term post-traumatic stress disorder: preliminary observations.  Brain Behav Immun. 1998;  12 74-79
    CrossrefPubMedGoogle Scholar
  • 49 Watson I P, Muller H K, Jones I CH, Bradley A J. Cell-mediated immunity in combat veterans with post-traumatic stress disorder.  Med J Australia. 1993;  159 513-516
    PubMedGoogle Scholar
  • 50 Gotovac K, Sabioncello A, Rabatic S. et al . Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD).  Clin Exp Immunol. 2003;  131 335-339
    CrossrefPubMedGoogle Scholar
  • 51 Maes M, Lin A H, Delmeire L. et al . Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events.  Biol Psychiatry. 1999 a;  45 833-839
    CrossrefPubMedGoogle Scholar
  • 52 Lehmann-Facius H. Liquoruntersuchungen bei destruktiven Erkrankungen des Nervensystems, besonders bei Schizophrenien.  Neurologie Psychiatrie. 1937;  157 109-115
    PubMedGoogle Scholar
  • 53 Torrey E F, Miller J, Rawlings R, Yolken R H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature.  Schizophr Res. 1997;  28 1-38
    CrossrefPubMedGoogle Scholar
  • 54 Wright P, Gill M, Murray R M. Schizophrenia: Genetics and the maternal immune response to viral infection.  Am J Med Gen. 1993;  48 40-46
    CrossrefPubMedGoogle Scholar
  • 55 Kirch D G. Infection and autoimmunity as etiologic factors in schizophrenia: A review and reappraisal.  Schizophr Bull. 1993;  19 355-370
    PubMedGoogle Scholar
  • 56 Rothermundt M, Arolt V, Bayer T A. Review of immunological and immunopathological findings in schizophrenia.  Brain Behav Immun. 2001 a;  15 319-339
    CrossrefPubMedGoogle Scholar
  • 57 Ganguli R, Rabin B S. Increased serum interleukin-2 receptor in schizophrenic and brain damaged subjects.  Arch Gen Psychiatry. 1989;  46 291-292
    PubMedGoogle Scholar
  • 58 Rapaport M H, McAllister C G, Pickar D. et al . Elevated levels of soluble interleukin-2 receptors in schizophrenia.  Arch Gen Psychiatry. 1989;  46 291-292
    PubMedGoogle Scholar
  • 59 Hornberg M, Arolt V, Wilke I. et al . Lymphokine production in leukocyte cultures of patients with schizophrenia.  Schizophr Res. 1995;  15 237-242
    CrossrefPubMedGoogle Scholar
  • 60 McAllister C G, Kammen D P van, Rehn T J. et al . Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.  Am J Psychiatry. 1995;  152 1291-1297
    PubMedGoogle Scholar
  • 61 Rapaport M H, Lohr J B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.  Acta Psychiatr Scand. 1994;  90 311-315
    PubMedGoogle Scholar
  • 62 Schwarz M J, Ackenheil M, Riedel M, Müller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia.  Neurosci Lett. 1998;  253 201-203
    CrossrefPubMedGoogle Scholar
  • 63 Müller N, Riedel M, Hadjamu M. et al . Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia.  Am J Psychiatry. 1999 b;  156 634-636
    PubMedGoogle Scholar
  • 64 Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders.  Progr Neuropsychopharmacol Biol Psychiatry. 1998;  22 1-33
    CrossrefPubMedGoogle Scholar
  • 65 Müller N, Riedel M, Ackenheil M, Schwarz M J. The role of immune function in schizophrenia: an overview.  Eur Arch Psychiatry Clin Neurosci. 1999 a;  249, Suppl 4 62-68
    CrossrefPubMedGoogle Scholar
  • 66 Moises H W, Schindler L, Leroux M, Kirchner H. Decreased production of interferon alpha and interferon gamma in leukocyte cultures of schizophrenic patients.  Acta Psychiatr Scand. 1985;  72 45-50
    PubMedGoogle Scholar
  • 67 Villemain F, Chatenoud L, Guillibert E. et al . Decreased production of interleukin-2 in schizophrenia.  Ann N Y Acad Sci. 1987;  469 669-675
    PubMedGoogle Scholar
  • 68 Villemain F, Chatenoud L, Galinowski A. et al . Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production.  Am J Psychiatry. 1989;  146 609-616
    PubMedGoogle Scholar
  • 69 Ganguli R, Rabin B S, Belle S H. Decreased interleukin-2 production in schizophrenic patients.  Biol Psychiatry. 1989;  26 427-430
    CrossrefPubMedGoogle Scholar
  • 70 Licinio J, Seibyl J P, Altemus M. et al . Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients.  Am J Psychiatry. 1993;  150 1408-1410
    PubMedGoogle Scholar
  • 71 El-Mallakh R S, Suddath R L, Wyatt R J. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.  Prog Neuropsychopharmacol Biol Psychiatry. 1993;  17 383-391
    CrossrefPubMedGoogle Scholar
  • 72 Barak V, Barak Y, Levine J. et al . Changes in interleukin-1beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients.  J Basic Clin Physiol Pharmacol. 1995;  6 61-69
    PubMedGoogle Scholar
  • 73 Rapaport M H, McAllister C G, Pickar D. et al . CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.  Schizophr Res. 1997;  25 123-129
    CrossrefPubMedGoogle Scholar
  • 74 Wilke I, Arolt V, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenics.  Eur Arch Psychiatry Clin Neurosci. 1996;  246 279-284
    CrossrefPubMedGoogle Scholar
  • 75 Rothermundt M, Arolt V, Weitzsch C. et al . Decreased production of IFN-γ in acute schizophrenia.  Biol Psychiatry. 1996;  40 1294-1297
    CrossrefPubMedGoogle Scholar
  • 76 Rothermundt M, Arolt V, Weitzsch C. et al . Immunological dysfunction in schizophrenia: a systematic approach.  Neuropsychobiol. 1998;  37 186-193
    PubMedGoogle Scholar
  • 77 Rothermundt M, Arolt V, Leadbeater J. et al . Cytokine production in unmedicated and treated schizophrenic patients.  Neuroreport. 2000;  11 3385-3388
    PubMedGoogle Scholar
  • 78 Arolt V, Weitzsch C, Wilke I. et al . Production of interferon-gamma in families with multiple occurrence of schizophrenia.  Psychiatry Res. 1997 a;  66 145-151
    CrossrefPubMedGoogle Scholar
  • 79 Arolt V, Rothermundt M, Wandinger K P, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment.  Mol Psychiatry. 2000;  5 150-158
    CrossrefPubMedGoogle Scholar
  • 80 Sivieri S, Ferrarini A M, Gallo P. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.  Mult Sclerosis. 1998;  4 7-11
    PubMedGoogle Scholar
  • 81 Schwarz M J, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders.  Brain Behav Immun. 2001;  15 340-370
    CrossrefPubMedGoogle Scholar
  • 82 Andreoli A V, Keller S E, Rabaeus M. et al . Immunity, major depression, and panic disorder comorbidity.  Biol Psychiatry. 1992;  31 896-908
    CrossrefPubMedGoogle Scholar
  • 83 Surman O S, Williams J, Sheehan D V. et al . Immunological response to stress in agoraphobia and panic attacks.  Biol Psychiatry. 1986;  21 768-774
    CrossrefPubMedGoogle Scholar
  • 84 Brambilla F, Bellodi L, Perna G. et al . Psychoimmunoendocrine aspects of panic disorder.  Neuropsychobiol. 1992;  26 12-22
    PubMedGoogle Scholar
  • 85 Koh K B, Lee B K. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders.  Psychosom Med. 1998;  60 479-483
    PubMedGoogle Scholar
  • 86 Rapaport M H. Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers.  Biol Psychiatry. 1998;  43 458-463
    CrossrefPubMedGoogle Scholar
  • 87 Rapaport M H, Stein M B. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia.  Anxiety. 1994 a;  1 50-53
    PubMedGoogle Scholar
  • 88 Rapaport M H, Stein M B. Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder.  Anxiety. 1994 b;  1 22-25
    PubMedGoogle Scholar
  • 89 Weizman R, Laor N, Wiener Z. et al . Cytokine production in panic disorder patients.  Clin Neuropharmacol. 1999;  22 107-109
    PubMedGoogle Scholar
  • 90 Barber Y, Toren P, Achiron A. et al . T cell subsets in obsessive-compulsive disorder.  Neuropsychobiol. 1996;  34 63-66
    PubMedGoogle Scholar
  • 91 Ravindran A V, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls.  J Affect Disord. 1999;  52 1-10
    CrossrefPubMedGoogle Scholar
  • 92 Maes M, Meltzer H Y, Bosmans E. Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations.  Neuropsychobiol. 1994 b;  30 57-60
    PubMedGoogle Scholar
  • 93 Monteleone P, Catapone F, Fabrazzo M. et al . Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder.  Neuropsychobiol. 1998;  37 182-185
    PubMedGoogle Scholar
  • 94 Weizman R, Laor N, Barber Y. et al . Cytokine production in obsessive-compulsive disorder.  Biol Psychiatry. 1996;  40 908-912
    CrossrefPubMedGoogle Scholar
  • 95 Arolt V, Weitzsch C, Rothermundt M. et al . Interferon-gamma in schizophrenia.  Recent Adv Biol Psychiatry. 1997 b;  18 57-66
    PubMedGoogle Scholar
  • 96 Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol.  Immunopharmacol. 1997;  37 75-86
    PubMedGoogle Scholar
  • 97 Nozaki H, Hozumi K, Nishimura T, Habu S. Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice.  Brain Behav Immunity. 1996;  10 17-26
    PubMedGoogle Scholar
  • 98 Maes M, Bosmans E, Calabrese J. et al . Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.  J Psychiatr Res. 1995 a;  29 141-152
    CrossrefPubMedGoogle Scholar
  • 99 Müller N, Empl M, Riedel M. et al . Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 308-313
    CrossrefPubMedGoogle Scholar
  • 100 Pollmächer T, Hinze-Selch D, Fenzel T. et al . Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.  Am J Psychiatry. 1997 b;  154 1763-1765
    PubMedGoogle Scholar
  • 101 Ghosh N, Chattopadhyay U. Enhancement of immune response by phenothiazine administration in vivo.  In vivo. 1993;  7 435-440
    PubMedGoogle Scholar
  • 102 Tarazona R, Gonzales-Garcia A, Zamzami N. et al . Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo.  J Immunol. 1995;  154 861-870
    PubMedGoogle Scholar
  • 103 Bessler H, Levental Z, Karp L. et al . Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.  Biol Psychiatry. 1995;  38 297-302
    CrossrefPubMedGoogle Scholar
  • 104 Ganguli R, Bra J S, Solomon W. et al . Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production.  Psychiatry Res. 1992;  44 113-123
    CrossrefPubMedGoogle Scholar
  • 105 Rudolf S, Peters M, Rothermundt M. et al . The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro.  Neuropsychobiol. 2002;  46 180-181
    PubMedGoogle Scholar
  • 106 Maes M, Bosmans E, Ranjan R. et al . Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs.  Schizophr Res. 1996;  21 39-50
    CrossrefPubMedGoogle Scholar
  • 107 Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.  J Clin Psychopharmacol. 1996;  16 403-409
    CrossrefPubMedGoogle Scholar
  • 108 Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.  Pharmacopsychiatry. 1997 a;  30 118-121
    PubMedGoogle Scholar
  • 109 Maes M, Meltzer H Y, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.  Acta Psychiatr Scand. 1994 a;  89 346-351
    PubMedGoogle Scholar
  • 110 Maes M, Bosmans E, Kenis G. et al . In vivo immunomodulatory effects of clozapine in schizophrenia.  Schizophr Res. 1997 b;  26 221-225
    CrossrefPubMedGoogle Scholar
  • 111 Hinze-Selch D, Becker E W, Stein G M. et al . Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients.  Neuropsychopharmacol. 1998;  19 114-122
    CrossrefPubMedGoogle Scholar
  • 112 Monteleone P, Fabrazzo M, Tortolla A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.  Psychiatry Res. 1997;  71 11-17
    CrossrefPubMedGoogle Scholar
  • 113 Kubera M, Basta-Kaim A, Skowron-Cendrzak A. et al . Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity.  Pol J Pharmacol. 1995;  47 321-326
    PubMedGoogle Scholar
  • 114 Kubera M, Symbirtsev A, Basta-Kaim A. et al . Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression.  Pol J Pharmacol. 1996;  48 503-506
    PubMedGoogle Scholar
  • 115 Sacerdote P, Bianchi M, Panerai A E. In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat.  Eur J Pharmacol. 1997;  319 287-290
    CrossrefPubMedGoogle Scholar
  • 116 Eisen J N, Irwin J, Quay J, Livnat S. The effect of antidepressants on immune function in mice.  Biol Psychiatry. 1989;  26 805-817
    CrossrefPubMedGoogle Scholar
  • 117 Henderson D C, Edwards R G, Weston B J, Dewdney J M. Immunological studies on paroxetine, a novel anti-depressant drug.  Int J Immunopharmacol. 1998;  10 361-367
    PubMedGoogle Scholar
  • 118 Xiao L, Eneroth P. Tricyclic antidepressants inhibit human natural killer cells.  Toxicol Appl Pharmacol. 1996;  137 157-162
    CrossrefPubMedGoogle Scholar
  • 119 Xia Z, DePierre J W, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells.  Immunopharmacol. 1996;  34 27-37
    CrossrefPubMedGoogle Scholar
  • 120 Miller A H, Asnis G M, Praag H M van, Norin A J. Influence of desmethylimipramine on natural killer cell activity.  Psychiatry Res. 1986;  19 9-15
    CrossrefPubMedGoogle Scholar
  • 121 Maes M, Song C, Lin A H. et al . Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.  Neuropsychopharmacol. 1999 b;  20 370-379
    CrossrefPubMedGoogle Scholar
  • 122 Pariante C M, Miller A H. Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment.  Eur Neuropsychopharmacol. 1995;  5, Suppl 83-88
    CrossrefPubMedGoogle Scholar
  • 123 Landmann R, Schaub B, Link S, Wacher H R. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy.  Biol Psychiatry. 1997;  41 675-681
    PubMedGoogle Scholar
  • 124 Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract.  J Geriatr Psychiatry Neurol. 1994;  7, Suppl 1 60-62
    PubMedGoogle Scholar
  • 125 Ravindran A V, Griffiths J, Merali Z, Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment.  Psychosom Med. 1995;  57 555-563
    CrossrefPubMedGoogle Scholar
  • 126 Sluzewska A, Rybakowski J K, Laciak M. et al . Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.  Ann N Y Acad Sci. 1995;  762 474-476
    PubMedGoogle Scholar
  • 127 Andreoli A V, Keller S E, Rabaeus M C. et al . Depression and Immunity: Age, Severity, and Clinical Course.  Brain Behav Immun. 1993;  7 279-292
    CrossrefPubMedGoogle Scholar
  • 128 Bauer M E, Gauer G J, Luz C. et al . Evaluation of immune parameters in depressed Patients.  Life Sci. 1995;  57 665-674
    CrossrefPubMedGoogle Scholar
  • 129 Caldwell C L, Irwin M, Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia.  Biol Psychiatry. 1991;  30 1131-1138
    CrossrefPubMedGoogle Scholar
  • 130 Castle S, Wilkins S, Heck E. et al . Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+ CD8+).  Clin Exp Immunol. 1995;  101 487-493
    PubMedGoogle Scholar
  • 131 Evans D L, Folds J D, Petitto J M. et al . Circulating Natural Killer Cell Phenotypes in Men and Women With Major Depression.  Arch Gen Psychiatry. 1992;  49 388-395
    PubMedGoogle Scholar
  • 132 Hickie I, Hickie C, Lloyd A. et al . Impaired in vivo immune responses in patients with melancholia.  Br J Psychiatry. 1993;  162 651-657
    PubMedGoogle Scholar
  • 133 Irwin M, Patterson T, Smith T L. et al . Reduction of immune function in life stress and depression.  Biol Psychiatry. 1990;  27 22-30
    CrossrefPubMedGoogle Scholar
  • 134 Kanba S, Manki H, Shintani F. et al . Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode.  Psychol Med. 1998;  28 481-484
    CrossrefPubMedGoogle Scholar
  • 135 Kook A I, Mizruchin A, Odnopozov N. et al . Depression and immunity: the biochemical interrelationship between the central nervous system and the immune system.  Biol Psychiatry. 1995;  37 817-819
    CrossrefPubMedGoogle Scholar
  • 136 Levy E M, Borrelli D J, Mirin S M. et al . Biological Measures and Cellular Immunological Function in Depressed Psychiatric Inpatients.  Psychiatry Res. 1991;  36 157-167
    CrossrefPubMedGoogle Scholar
  • 137 Maes M, Bosmans E, Suy E. et al . A further exploration of the relationships between immune parameters and the HPA-axis activity in depressed patients.  Psychol Med. 1991 b;  21 313-320
    PubMedGoogle Scholar
  • 138 Maes M, Stevens W, Peeters D. et al . A Study On The Blunted Natural Killer Cell Activity In Severely Depressed Patients.  Life Sci. 1992 b;  50 505-513
    CrossrefPubMedGoogle Scholar
  • 139 Maes M, Scharpe S, Meltzer H Y, Cosyns P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression.  Biol Psychiatry. 1993 b;  34 690-701
    CrossrefPubMedGoogle Scholar
  • 140 Miller A H, Asnis G M, Lackner C. et al . Depression, natural killer cell activity, and cortisol secretion.  Biol Psychiatry. 1991;  29 878-886
    CrossrefPubMedGoogle Scholar
  • 141 Natelson B H, LaManca J J, Denny T N. et al . Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis.  Am J Med. 1998;  105 43S-49S
    CrossrefPubMedGoogle Scholar
  • 142 Ravindran A V, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features.  Psychosom Med. 1998;  60 283-289
    PubMedGoogle Scholar
  • 143 Reynaert C, Janne P, Bosly A. et al . From health locus of control to immune control: internal locus of control has a buffering effect on natural killer cell activity decrease in major depression.  Acta Psychiatr Scand. 1995;  92 294-300
    PubMedGoogle Scholar
  • 144 Schleifer S J, Keller S E, Bartlett J A. et al . Immunity in Young Adults With Major Depressive Disorder.  Am J Psychiatry. 1996;  153 477-482
    PubMedGoogle Scholar
  • 145 Spurrell M T, Creed F H. Lymphocyte response in depressed patients and subjects anticipating bereavement.  Br J Psychiatry. 1993;  162 60-64
    PubMedGoogle Scholar
  • 146 Wodarz N, Rupprecht R, Kornhuber J. et al . Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression.  J Affect Disord. 1991;  22 241-248
    CrossrefPubMedGoogle Scholar

Prof. Dr. Volker Arolt

Klinik und Poliklinik für Psychiatrie und Psychotherapie · Universitätsklinikum Münster

Albert-Schweitzer-Straße 11

48129 Münster

Email: arolt@uni-muenster.de

URL: http://medweb.uni-muenster.de/institute/psych/index.html

      >